Calogero Aldo E, Burgio Giovanni, Condorelli Rosita A, Cannarella Rossella, La Vignera Sandro
a Department of Clinical and Experimental Medicine , University of Catania , Catania , Italy.
Aging Male. 2018 Dec;21(4):272-280. doi: 10.1080/13685538.2018.1432586. Epub 2018 Jan 29.
This article summarizes years of challenging research on erectile dysfunction (ED), a condition that has an important social and cultural relevance. Preclinical and clinical research progress has led to new therapeutic approaches to ED in patients with different comorbidities and particularly in those with low urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH). These goals were possible only by combined work of specialists and researchers of different and intertwined medical disciplines. Currently, tadalafil (5 mg/d) is the best choice; other phosphodiesterase-5 inhibitors (PDE5i) are not included among options, despite the growing evidence of therapeutic effects. Different regimens of tadalafil may be prescribed based on patient needs, severity of LUTS/BPH - ED profile, and clinical experience. An integrated approach is necessary to choose for a combined therapy with PDE5i and α-blockers following urological and cardiac counseling in terms of outcomes and adverse effects.
本文总结了多年来对勃起功能障碍（ED）这一具有重要社会和文化意义的病症所进行的具有挑战性的研究。临床前和临床研究进展已带来针对不同合并症患者，尤其是下尿路症状（LUTS）/良性前列腺增生（BPH）患者的勃起功能障碍新治疗方法。只有通过不同且相互交织的医学学科的专家和研究人员的共同努力，这些目标才得以实现。目前，他达拉非（5毫克/天）是最佳选择；尽管治疗效果的证据越来越多，但其他磷酸二酯酶-5抑制剂（PDE5i）未被列入选择范围。可根据患者需求、LUTS/BPH - ED概况的严重程度以及临床经验来开具不同的他达拉非治疗方案。就结果和不良反应而言，在进行泌尿外科和心脏咨询后，选择PDE5i与α受体阻滞剂联合治疗需要采用综合方法。
